Presentations span Parkinson's disease and ALS clinical and real-world evidence
Oral platform sessions will highlight results from Phase 3 BouNDless trial in PD and real-world findings from preliminary analysis of RADICAVA® (edaravone) treatment in ALS
JERSEY CITY, N.J., April 12, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced...